NEWS - Draft NICE guidance does not recommend Orencia (abatacept) for second-line use in RA

[Guest guest]

Draft NICE Guidance Does Not Recommend Abatacept For Second-Line Use

In Rheumatoid Arthritis

MedicalNewsToday.com

Article Date: 30 Mar 2011 - 3:00 PDT

The National Institute for Health and Clinical Excellence (NICE) has

today (30 March 2011) opened a consultation on draft guidance which

does not recommend abatacept (Orencia, Bristol-Myers Squibb), in

combination with methotrexate, for the treatment of moderate to severe

active rheumatoid arthritis in adults whose disease has responded

inadequately to one or more conventional non-biological disease

modifying anti-rheumatic drugs (DMARDs) including methotrexate.

***************************************

Read the full article here:

http://www.medicalnewstoday.com/articles/220641.php

Not an MD